Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 90861

Title: Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 07807707
Position: Peer Reviewer
Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Mexico

Manuscript submission date: 2023-12-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-17 14:08

Reviewer performed review: 2023-12-19 14:33

Review time: 2 Days

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No creativity or innovation

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This mini review investigated the status of IFN-γsignaling pathway in LUAD. And the reduction in IFNGR1 expression appears to be associated with LUAD progression, affecting defenses against viruses such as SARS-CoV-2. This manuscript exhibited some innovative points and clinical importance especially in the relations between LUAD and SARS-CoV-2, while it still has some defects which should be revised. 1.The wording should be modified to be more precise and understandable, and the wrongly written words should be corrected. 2.The introduction for LUAD was too lengthy and seemed little relevance with the theme. 3.A table regarding the expression profile of IFNGR1 in cancer is recommended to list. 4.What about the IFNGR2 expression in cancer? 5.There are polymorphisms in IFNGR1 promoter in cancer, what about its mutation in cancer? 6.This manuscript has described the ubiquitin and palmitoylation in IFNGR1 regulation, are there other post-translational modifications? 7.Since there were deregulation of IFN-γsignaling pathway in other kinds of cancer,why focusing on LUAD? 8.What is the prognostic value of IFNGR1 expression in LUAD, and are there cooperative predictive value with JAK1/2? 9.The quality of Figures should be improved.